Literature DB >> 24740517

Rational design, synthesis, and evaluation of tetrahydroxamic acid chelators for stable complexation of zirconium(IV).

François Guérard1, Yong-Sok Lee, Martin W Brechbiel.   

Abstract

Metals of interest for biomedical applications often need to be complexed and associated in a stable manner with a targeting agent before use. Whereas the fundamentals of most transition-metal complexation processes have been thoroughly studied, the complexation of Zr(IV) has been somewhat neglected. This metal has received growing attention in recent years, especially in nuclear medicine, with the use of (89) Zr, which a β(+) -emitter with near ideal characteristics for cancer imaging. However, the best chelating agent known for this radionuclide is the trishydroxamate desferrioxamine B (DFB), the Zr(IV) complex of which exhibits suboptimal stability, resulting in the progressive release of (89) Zr in vivo. Based on a recent report demonstrating the higher thermodynamic stability of the tetrahydroxamate complexes of Zr(IV) compared with the trishydroxamate complexes analogues to DFB, we designed a series of tetrahydroxamic acids of varying geometries for improved complexation of this metal. Three macrocycles differing in their cavity size (28 to 36-membered rings) were synthesized by using a ring-closing metathesis strategy, as well as their acyclic analogues. A solution study with (89) Zr showed the complexation to be more effective with increasing cavity size. Evaluation of the kinetic inertness of these new complexes in ethylenediaminetetraacetic acid (EDTA) solution showed significantly improved stabilities of the larger chelates compared with (89) Zr-DFB, whereas the smaller complexes suffered from insufficient stabilities. These results were rationalized by a quantum chemical study. The lower stability of the smaller chelates was attributed to ring strain, whereas the better stability of the larger cyclic complexes was explained by the macrocyclic effect and by the structural rigidity. Overall, these new chelating agents open new perspectives for the safe and efficient use of (89) Zr in nuclear imaging, with the best chelators providing dramatically improved stabilities compared with the reference DFB.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  chelates; imaging agents; ligand design; quantum chemistry; zirconium

Mesh:

Substances:

Year:  2014        PMID: 24740517      PMCID: PMC4123539          DOI: 10.1002/chem.201304115

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  20 in total

Review 1.  Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals.

Authors:  S Liu; D S Edwards
Journal:  Bioconjug Chem       Date:  2001 Jan-Feb       Impact factor: 4.774

Review 2.  PET imaging with ⁸⁹Zr: from radiochemistry to the clinic.

Authors:  Melissa A Deri; Brian M Zeglis; Lynn C Francesconi; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2012-09-19       Impact factor: 2.408

Review 3.  Mapping biological behaviors by application of longer-lived positron emitting radionuclides.

Authors:  Yang Zhou; Kwamena E Baidoo; Martin W Brechbiel
Journal:  Adv Drug Deliv Rev       Date:  2012-11-02       Impact factor: 15.470

4.  PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab.

Authors:  Tapan K Nayak; Kayhan Garmestani; Diane E Milenic; Martin W Brechbiel
Journal:  J Nucl Med       Date:  2012-01       Impact factor: 10.057

5.  Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.

Authors:  Maria J W D Vosjan; Lars R Perk; Gerard W M Visser; Marianne Budde; Paul Jurek; Garry E Kiefer; Guus A M S van Dongen
Journal:  Nat Protoc       Date:  2010-03-25       Impact factor: 13.491

6.  In vivo biodistribution and accumulation of 89Zr in mice.

Authors:  Diane S Abou; Thomas Ku; Peter M Smith-Jones
Journal:  Nucl Med Biol       Date:  2011-03-03       Impact factor: 2.408

7.  Investigation of Zr(IV) and 89Zr(IV) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging.

Authors:  François Guérard; Yong-Sok Lee; Raphaël Tripier; Lawrence P Szajek; Jeffrey R Deschamps; Martin W Brechbiel
Journal:  Chem Commun (Camb)       Date:  2012-12-19       Impact factor: 6.222

8.  H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu.

Authors:  Eric W Price; Brian M Zeglis; Jason S Lewis; Michael J Adam; Chris Orvig
Journal:  Dalton Trans       Date:  2014-01-07       Impact factor: 4.390

9.  Standardized methods for the production of high specific-activity zirconium-89.

Authors:  Jason P Holland; Yiauchung Sheh; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2009-07-29       Impact factor: 2.408

10.  Annotating MYC status with 89Zr-transferrin imaging.

Authors:  Jason P Holland; Michael J Evans; Samuel L Rice; John Wongvipat; Charles L Sawyers; Jason S Lewis
Journal:  Nat Med       Date:  2012-09-23       Impact factor: 53.440

View more
  25 in total

1.  Macrocycle-Based Hydroxamate Ligands for Complexation and Immunoconjugation of 89Zirconium for Positron Emission Tomography (PET) Imaging.

Authors:  Eszter Boros; Jason P Holland; Nathaniel Kenton; Nicholas Rotile; Peter Caravan
Journal:  Chempluschem       Date:  2016-01-25       Impact factor: 2.863

Review 2.  In vivo imaging with antibodies and engineered fragments.

Authors:  Amanda C Freise; Anna M Wu
Journal:  Mol Immunol       Date:  2015-04-28       Impact factor: 4.407

3.  Investigation of the complexation of natZr(iv) and 89Zr(iv) by hydroxypyridinones for the development of chelators for PET imaging applications.

Authors:  F Guérard; M Beyler; Y-S Lee; R Tripier; J-F Gestin; M W Brechbiel
Journal:  Dalton Trans       Date:  2017-04-05       Impact factor: 4.390

4.  Multifunctional Desferrichrome Analogues as Versatile 89Zr(IV) Chelators for ImmunoPET Probe Development.

Authors:  Casey J Adams; Justin J Wilson; Eszter Boros
Journal:  Mol Pharm       Date:  2017-07-19       Impact factor: 4.939

5.  Polyazamacrocycle Ligands Facilitate 89Zr Radiochemistry and Yield 89Zr Complexes with Remarkable Stability.

Authors:  Darpan N Pandya; Kelly E Henry; Cynthia S Day; Stephen A Graves; Veronica L Nagle; Thomas R Dilling; Akesh Sinha; Brandie M Ehrmann; Nikunj B Bhatt; Yusuf Menda; Jason S Lewis; Thaddeus J Wadas
Journal:  Inorg Chem       Date:  2020-11-10       Impact factor: 5.165

6.  Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.

Authors:  Diane E Milenic; Kwamena E Baidoo; Young-Seung Kim; Martin W Brechbiel
Journal:  MAbs       Date:  2015       Impact factor: 5.857

7.  The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies.

Authors:  Brian M Zeglis; Jason S Lewis
Journal:  J Vis Exp       Date:  2015-02-12       Impact factor: 1.355

8.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

9.  Evaluation of a chloride-based 89Zr isolation strategy using a tributyl phosphate (TBP)-functionalized extraction resin.

Authors:  Stephen A Graves; Christopher Kutyreff; Kendall E Barrett; Reinier Hernandez; Paul A Ellison; Steffen Happel; Eduardo Aluicio-Sarduy; Todd E Barnhart; Robert J Nickles; Jonathan W Engle
Journal:  Nucl Med Biol       Date:  2018-06-18       Impact factor: 2.408

10.  A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89.

Authors:  Elaheh Khozeimeh Sarbisheh; Akam K Salih; Shvan J Raheem; Jason S Lewis; Eric W Price
Journal:  Inorg Chem       Date:  2020-07-28       Impact factor: 5.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.